Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Viking Therapeutics (VKTX) Misses Q2 EPS by 2c
August 9, 2018 4:08 PM EDTViking Therapeutics (NASDAQ: VKTX) reported Q2 EPS of ($0.13), $0.02 worse than the analyst estimate of ($0.11).
"Viking continued to make excellent progress with multiple programs in the second quarter," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "With respect to VK5211, our novel selective... More
